Thelansis

  Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. It is estimated that 150,750 new cases of CRC will be diagnosed in the US in 2020. Approximately 25% of patients have metastatic disease at diagnosis, approximately 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. HER2 overexpression in CRC detected by immune-histochemical (IHC) staining for HER2 protein and in-situ hybridization (ISH) for gene amplification or reverse transcription-polymerase chain reaction (RT-PCR) for overexpression of HER2 RNA. HER2 amplification and KRAS, NRAS, and BRAF mutations are mutually exclusive in advanced CRC. In addition, KRAS exon 2 wild-type metastatic CRC appears to enrich for HER2 amplification in the range of 4% to 9% of cases. The competitive landscape of HER2-Positive Metastatic Colorectal Cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tr...